ACADIA Pharmaceuticals Inc. (ACAD)’s Financial Results Comparing With Minerva Neurosciences Inc. (NASDAQ:NERV)

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) and Minerva Neurosciences Inc. (NASDAQ:NERV) are two firms in the Biotechnology that compete against each other. Below is a comparison of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ACADIA Pharmaceuticals Inc. 207.80M 15.42 248.57M -1.44 0.00
Minerva Neurosciences Inc. N/A 0.00 36.81M -1.19 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for ACADIA Pharmaceuticals Inc. and Minerva Neurosciences Inc.

Profitability

Table 2 shows us ACADIA Pharmaceuticals Inc. and Minerva Neurosciences Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
ACADIA Pharmaceuticals Inc. -119.62% -88.2% -75.5%
Minerva Neurosciences Inc. 0.00% -31.7% -22%

Risk and Volatility

ACADIA Pharmaceuticals Inc. has a 3.32 beta, while its volatility is 232.00%, thus making it more volatile than Standard and Poor’s 500. In other hand, Minerva Neurosciences Inc. has beta of 1.53 which is 53.00% more volatile than Standard and Poor’s 500.

Liquidity

6.1 and 6 are the respective Current Ratio and a Quick Ratio of ACADIA Pharmaceuticals Inc. Its rival Minerva Neurosciences Inc.’s Current and Quick Ratios are 26.2 and 26.2 respectively. Minerva Neurosciences Inc. has a better chance of clearing its pay short and long-term debts than ACADIA Pharmaceuticals Inc.

Analyst Ratings

Recommendations and Ratings for ACADIA Pharmaceuticals Inc. and Minerva Neurosciences Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
ACADIA Pharmaceuticals Inc. 0 3 3 2.50
Minerva Neurosciences Inc. 0 0 0 0.00

ACADIA Pharmaceuticals Inc. has a 21.78% upside potential and a consensus price target of $27.17.

Institutional and Insider Ownership

ACADIA Pharmaceuticals Inc. and Minerva Neurosciences Inc. has shares owned by institutional investors as follows: 86.7% and 79.9%. Insiders owned roughly 0.1% of ACADIA Pharmaceuticals Inc.’s shares. On the other hand, insiders owned about 0.1% of Minerva Neurosciences Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ACADIA Pharmaceuticals Inc. -1.47% -6.1% 34.62% 5.09% -37.59% -37.63%
Minerva Neurosciences Inc. 0.51% -22.59% -18.46% -5.92% 41.96% 31.4%

For the past year ACADIA Pharmaceuticals Inc. has -37.63% weaker performance while Minerva Neurosciences Inc. has 31.4% stronger performance.

Summary

Minerva Neurosciences Inc. beats on 7 of the 10 factors ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The companyÂ’s lead product candidate includes MIN-101, a compound for the treatment of patients with schizophrenia that completed Phase IIb clinical trial. It also offers MIN-202, which completed Phase IIa clinical trial for treating primary insomnia, as well as completed Phase 1b used for the treatment of major depressive disorder; and MIN-117, a compound that completed Phase IIa clinical trial for the treatment of patients suffering from major depressive disorder. The companyÂ’ preclinical stage product includes MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of ParkinsonÂ’s disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.